Key facts
- This page summarizes Lisa von Moltke's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 19 Feb 2025, 20:05.
Lisa von Moltke - 15 Feb 2025 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Reporting relationship
- Executive Vice President and Chief Medical Officer
- Issuer ticker
- MCRB
- Reported as of
- 15 Feb 2025
- Net transaction value
- -$3,579
- SEC form
- 4
- Accepted by SEC
- 19 Feb 2025, 20:05:09 UTC
- Prior SEC filing
- 11 Feb 2025
- Next SEC filing
- 21 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas J. DesRosier, attorney-in-fact for Lisa von Moltke
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lisa von Moltke filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 19 Feb 2025.
Change
- Previous filing in this sequence was filed on 11 Feb 2025.
- Current net transaction value: -$3,579.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MCRB
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +2,969
- Change %
- +9.2%
- Price
- Shares after
- 35,384
- Date
- 15 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
MCRB
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +8,907
- Change %
- +25%
- Price
- Shares after
- 44,291
- Date
- 15 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
MCRB
transaction
Common Stock
Sale
- Transaction value
- $3,579
- Shares
- -4,416
- Change %
- -10%
- Price
- $0.8105
- Shares after
- 39,875
- Date
- 18 Feb 2025
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MCRB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -2,969
- Change %
- -11%
- Price
- $0.000000
- Shares after
- 23,750
- Date
- 15 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,969
- Exercise price
- Footnotes
- F1, F4
MCRB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -8,907
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 26,718
- Date
- 15 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,907
- Exercise price
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
Footnote F3
The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.8376, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Footnote F5
The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
SEC remarks
Executive Vice President and Chief Medical Officer